SAA1 and metabolomic signatures predict hyperprogression with immunotherapy in pan cancers

Xiaoqing Wang; Longshan Zhang; Liwei Liao; Nan Li; Tingxi Tang; Jianda Sun; Zhenhua Zhou; Yang Liu; Jihong Huang; Yingqiao Wang; Zekai Chen; Hanbin Zhang; Ting Xiao; Yunming Tian; Xiuting Zheng; Yi Yuan; Linlin Xiao; Laiyu Liu; Jian Guan

doi:10.1002/ctm2.1624

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (3) : e1624 DOI: 10.1002/ctm2.1624

LETTER TO THE JOURNAL

SAA1 and metabolomic signatures predict hyperprogression with immunotherapy in pan cancers

Author information +

History +

PDF

Cite this article

Download citation ▾

Xiaoqing Wang, Longshan Zhang, Liwei Liao, Nan Li, Tingxi Tang, Jianda Sun, Zhenhua Zhou, Yang Liu, Jihong Huang, Yingqiao Wang, Zekai Chen, Hanbin Zhang, Ting Xiao, Yunming Tian, Xiuting Zheng, Yi Yuan, Linlin Xiao, Laiyu Liu, Jian Guan. SAA1 and metabolomic signatures predict hyperprogression with immunotherapy in pan cancers. Clinical and Translational Medicine, 2024, 14(3): e1624 DOI:10.1002/ctm2.1624

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Champiat S, Ferrara R, Massard C, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018;15:748-762.

[2]	Wang X, Wang F, Zhong M, et al. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. Mol Cancer. 2020;19:81.

[3]	Billan S, Kaidar-Person O, Gil Z. Treatment after progression in the era of immunotherapy. Lancet Oncol. 2020;21:e463-e476.

[4]	Kim CG, Kim C, Yoon SE, et al. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J Hepatol. 2021;74:350-359.

[5]	Shen P, Han L, Ba X, et al. Hyperprogressive disease in cancers treated with immune checkpoint inhibitors. Front Pharmacol. 2021;12:678409.

[6]	Notarnicola M, De Nunzio V, Tutino V, et al. Integrated small dense low-density lipoprotein profile in cardiovascular disease and cancer: a longitudinal study. Anticancer Res. 2019;39:6035-6039.

[7]	VanEvery H, Yang W, Su J, et al. Low-density lipoprotein cholesterol and the risk of rheumatoid arthritis: a prospective study in a Chinese cohort. Nutrients. 2022;14(6):1240.

[8]	Duran EK, Aday AW, Cook NR, et al. Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2020;75:2122-2135.

[9]	Sack GH. Serum amyloid A—a review. Mol Med. 2018;24:46.

[10]	Jiang B, Wang D, Hu Y, et al. Serum amyloid A1 exacerbates hepatic steatosis via TLR4-mediated NF-κB signaling pathway. Mol Metab. 2022;59:101462.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.